Diligence memo · auto-generated · as of July 2, 2026
Medifacts International, Inc.
Medifacts International, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Medifacts International, Inc. operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Medifacts International, Inc. has raised $5.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2009-06-22.
Most recent recorded round closed around 2009-06-22.
Valuation (modeled)modeled
Provath models Medifacts International, Inc. at approximately $181M (range $5.5M–$983M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Series A Biotechnology companies in 2007–2009 (35 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 17.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 44% of Biotechnology peers (4293 compared).
Modeled value ranks above 71% of those peers.
Closest niche peers: Complete Genomics Inc, BioTrove, Inc., Aliva Biopharmaceuticals, LLC, Molecular Biometrics Inc, Bioimagene Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.